MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction disruptor sensitizes insulin signaling in skeletal muscle = MG53-IRS1의 단백질 결합 억제물질의 인슐린 신호 개선효능

Cited 14 time in scopus
Metadata Downloads
Title
MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) interaction disruptor sensitizes insulin signaling in skeletal muscle = MG53-IRS1의 단백질 결합 억제물질의 인슐린 신호 개선효능
Author(s)
H Lee; J J Park; N Nguyen; J S Park; J Hong; S H Kim; W Y Song; H J Kim; Kwangman Choi; Sungchan Cho; B W Kim; Y G Ko
Bibliographic Citation
Journal of Biological Chemistry, vol. 291, no. 52, pp. 26627-26635
Publication Year
2016
Abstract
Mitsugumin 53 (MG53) is an E3 ligase that interacts with and ubiquitinates insulin receptor substrate-1 (IRS-1) in skeletal muscle; thus, an MG53-IRS-1 interaction disruptor (MID), which potentially sensitizes insulin signaling with an elevated level of IRS-1 in skeletal muscle, is an excellent candidate for treating insulin resistance. To screen for an MID, we developed a bimolecular luminescence complementation system using an N-terminal luciferase fragment fused with IRS-1 and a C-terminal luciferase fragment fused with an MG53 C14A mutant that binds to IRS-1 but does not have E3 ligase activity. An MID, which was discovered using the bimolecular luminescence complementation system, disrupted the molecular association of MG53 with IRS-1, thus abolishing MG53-mediated IRS-1 ubiquitination and degradation. Thus, the MID sensitized insulin signaling and increased insulin-elicited glucose uptake with an elevated level of IRS-1 in C2C12 myotubes. These data indicate that this MID holds promise as a drug candidate for treating insulin resistance.
ISSN
0021-9258
Publisher
Amer Soc Biochemistry Molecular Biology Inc
Full Text Link
http://dx.doi.org/10.1074/jbc.M116.754424
Type
Article
Appears in Collections:
Ochang Branch Institute > Nucleic Acid Therapeutics Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.